RESUMO
The effect of suloctidil (120 mg/kg body weight PO for 3 weeks) on rat liver was investigated using biochemical and morphological methods: enzymatic activities characteristic of the main cellular compartments were used as biochemical markers of hepatocyte function and morphometry was applied to investigate morphological changes. No sign of hepatotoxicity was evidenced after suloctidil treatment (liver weight; cytochrome c oxidase; glucose 6-phosphatase; NADPH-cytochrome c reductase; D-amino acid oxidase; urate oxidase; fatty acid oxidation; peroxisomal number, volume and size distribution). Suloctidil increased catalase activity by 22% without morphologically detectable changes in the peroxisomes. After suloctidil treatment, slightly increased mitochondrial volume fraction and slightly decreased mitochondrial number were noted without significant changes in cytochrome c oxidase. Clofibrate, at the same dose, increased NADPH-cytochrome c reductase, catalase, acylCoA oxidase, mitochondrial and peroxisomal number and volume fraction, and decreased urate oxidase activity.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/patologia , Propanolaminas/toxicidade , Suloctidil/toxicidade , Animais , Doença Hepática Induzida por Substâncias e Drogas/enzimologia , Clofibrato/toxicidade , Fígado/enzimologia , Fígado/patologia , Masculino , Mitocôndrias Hepáticas/enzimologia , Ratos , Ratos EndogâmicosRESUMO
Suloctidil, a new vasoactive drug, shows certain properties which make it particularly suitable for using in migraine. The author administered Suloctidil in daily doses of 600 mg to 12 patients with migraine during 6 weeks. In 9 cases good results were obtained. Although further investigations are necessary, it seems already now that Suloctidil will enrich the armamentarium of antimigrainous drugs.